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It is well recognized that macrophages in many contexts in vitro and in vivo display a spec-
trum of inflammatory features and functional properties. A convenient system to group
together different subsets of macrophages has been the M1 (inflammatory)/M2 (anti-
inflammatory) classification. In addition to other sites of inflammation, it is now established
that atherosclerotic plaques contain both M1 and M2 macrophages. We review results
made possible by a number of recent mouse models of atherosclerotic regression that,
taken with other literature, have shown the M1/M2 balance in plaques to be dynamic,
with M1 predominating in disease progression and M2 in regression.The regulation of the
macrophage phenotype in plaques and the functional consequences of the M1 and M2
states in atherosclerosis will also be discussed.
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INTRODUCTION
Atherosclerotic cardiovascular diseases, which include myocardial
infraction and stroke, are the most common causes of mor-
bidity and mortality in western society and will soon be the
same world-wide. Atherosclerosis represents a failure to resolve
the inflammatory response in the arterial wall initiated by the
retention of apolipoprotein B (apoB)-containing lipoproteins (1).
These lipoproteins are taken up by tissue macrophages, which
ultimately become engorged with cholesterol (foam cells) and
activated. The continuing stimulus of the entry and retention of
apoB-lipoproteins fuels not only the accumulation of foam cells
to form a plaque, but also the chronicity and amplification of the
inflammatory response, which contribute to the vulnerability of
some plaques to rupture and cause acute tissue ischemia. The cen-
tral role of macrophages in atherosclerosis pathophysiology has,
therefore, focused attention on their properties in plaque initiation
and progression, and more recently, in regression (2–5).
The study of macrophages over the past decade is characterized
by a remarkable expansion of knowledge concerning their origin,
functional properties, and potential to both protect from and con-
tribute to disease [e.g., see in Ref. (6, 7)]. Admitting the complexity
of macrophage biology, for the purposes of this review, we have
restricted ourselves to considering how aspects of macrophage
polarization in the M1/M2 classification system (8) relate to ath-
erosclerosis progression and regression. In this system, which is
influenced by the Th1 and Th2 classification of lymphocytes,
macrophages can be grossly divided into pro-inflammatory, M1
cells and anti-inflammatory, M2 cells based mainly on in vitro
criteria (9). It is important to note, however, that while the classifi-
cation of lymphocytes into Th1 and Th2 preceded the classification
scheme of macrophages as M1/M2, the Th1 and Th2-like responses
result from polarization of macrophages to M1 and M2 states,
respectively. Furthermore, M1/M2 polarization is not dependent
on T cells, as has been demonstrated in Rag KO and other immune
deficient mice (8).
Polarization toward the M1 state is induced by several stim-
uli in vitro, including Toll-like receptor (TLR) ligands (such
as lipopolysaccharide, LPS) and interferon γ (potential endoge-
nous stimuli in atherosclerosis will be discussed below). M1
macrophages express several pro-inflammatory mediators, such as
inducible nitric oxide synthase, tumor necrosis factor-a (TNF-a),
interleukin-1b (IL-1b), IL-6, IL-12, and proteolytic enzymes. M1
macrophages have been found in both human and mouse ather-
osclerosis, and their secretion of the pro-inflammatory mediators
is thought to maintain local inflammation and the degradation of
extracellular matrix components, resulting in disease progression
[e.g., Ref. (10)], and ultimately, unstable plaques in humans. As
alluded to earlier, unstable plaques are at increased risk of rupture
and causing thrombosis, resulting in myocardial infarction and
stroke (11–14).
On the other side of the polarization spectrum, M2
macrophages are induced in vitro by Th2-type cytokines, such
as IL-4 and IL-13. T regulatory cells (Tregs) have also been impli-
cated in the induction of M2 polarization (15), possibly through
IL-10. M2 polarized macrophages have been characterized by their
expression of CD163, mannose receptor 1 (also known as CD206),
FIZZ1, and high levels of arginase 1. In addition, they secrete anti-
inflammatory cytokines, such as transforming growth factorβ, IL-1
receptor antagonist, IL-10, and have increased secretion of colla-
gen. Based particularly on the role of M2 macrophages in wound
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healing, the combination of the factors they express are thought
to be particularly suited for tissue repair, which is consistent with
their increased presence in regressing plaques in mouse models of
atherosclerosis (16, 17).
In addition to the M1 and M2 macrophages, oxidized phospho-
lipids present in oxidized LDL induce a macrophage phenotype
that is distinct from M1 or M2 phenotypes and that has been
termed Mox; these macrophages are characterized by the increases
in the expression of nuclear factor erythroid 2-related factor 2
(NRF2)-dependent genes and in reactive oxygen species, and are
found in the progressing plaques (18). Their role in atherosclerosis
regression, however, has not been established.
With this background, we will now turn to a more com-
plete consideration of the inflammatory states of macrophages
in atherosclerosis progression and regression.
ATHEROSCLEROSIS PROGRESSION
DRIVERS OF MACROPHAGE INFLAMMATION IN PROGRESSING
PLAQUES
As mentioned above, M1 macrophages are thought to have signif-
icant roles in progressing and vulnerable plaques (19). As noted
above, a potent inducer of the M1 state in vitro is LPS, which is
part of the outer membrane of Gram-negative bacteria, and which
binds and activates TLR4 (20). Dozens of studies have demon-
strated associations among high-fat diet, the metabolic syndrome,
and endotoxemia (i.e., increased levels of LPS in the plasma) (21–
23). It appears that a high-fat diet, the consumption of which leads
to metabolic syndrome in mouse models, also induces a change
in the gut bacterial flora, which, in turn, causes an increase in the
LPS plasma levels. Circumstantial considerations that support a
link between the metabolic syndrome and LPS signaling include
the increased cardiovascular risk in patients with the metabolic
syndrome and the positive association of TLR4 activity with ather-
osclerosis progression in mice and human beings (24–28). Despite
the evidence for association between LPS, atherosclerosis progres-
sion, and M1 polarization, a study in germ-free apoE-deficient
mice on low-fat chow diet showed increased atherosclerosis pro-
gression (29), suggesting that some bacteria in the gut flora have
an anti-inflammatory effect (30).
Cholesterol and macrophage activation
The most accepted and robust risk factor for atherosclerosis is
low-density lipoprotein-cholesterol (LDL-C). Thus, several stud-
ies have tried to understand how cholesterol can induce inflamma-
tion in general, and specifically to an activated state. The different
mechanisms by which cholesterol can drive macrophage activa-
tion could be divided into those direct – how cholesterol affects
macrophages, and indirect – how cholesterol affects other cell types
through which activation could be induced, for example by the
secretion of pro-inflammatory cytokines from T cells (Figure 1).
Direct mechanisms that link cholesterol to macrophage inflam-
mation. Accumulation of cholesterol leads to the formation of
crystals that are both intra- and extracellular. The presence of
cholesterol crystals in early lesions in Apoe-/- mice was recently
demonstrated (31, 32); in addition, it was shown that both
macrophage engulfment of cholesterol crystals and de novo for-
mation of intracellular cholesterol crystals activate the NLRP3
(NOD-, LRR- and pyrin domain-containing 3) inflammasome
(33). Activation of NLRP3, in turn, results in the secretion of
the pro-inflammatory cytokine IL-1β.This pathway appears to be
necessary for atherosclerosis progression, as LDL receptor (Ldlr)-
/- mice, transplanted with bone marrow cells deficient in IL-1β or
in components of the NLRP3 inflammasome, had reduced plaque
progression (31, 34).
A second direct mechanism that can explain macrophage acti-
vation by cholesterol is mediated through oxidized LDL. Oxidized
LDL is present in both human and mouse atheromas. LDL oxi-
dation is thought to be mediated by enzymes (such as 12/15-
lipoxygenase and myeloperoxidase) and by free radicals that are
abundant in the atherosclerotic plaque (35). Several studies have
demonstrated that oxidized LDL can act as a ligand for both the
scavenger receptors and TLRs on macrophages. Depending on the
extent of oxidation, species of oxidized LDL were found to be
agonists of CD14–TLR4–MD2 or CD36–TLR4–TLR6 complexes
in vitro; these complexes can induce a pro-inflammatory signal-
ing cascade involving IL-1 receptor-associated kinase 4 (IRAK4)
(36, 37), myeloid differentiation primary-response protein 88
(MYD88) (28, 38) and other signaling proteins, culminating in
activation of Nf-kB targets. Whole-body knock out mice of TLR2,
TLR4 and some of the signaling proteins mentioned here were
demonstrated to have reduced atherosclerosis progression (28, 39).
A third direct mechanism points toward the increase in plasma
membrane cholesterol. The change in the microenvironment of
TLRs (40, 41) renders them more sensitive to ligands, thereby
heightening the inflammatory responses.
Despite the predominance of data that show a direct link
between cholesterol and macrophage inflammation, there are a
number of studies that show the opposite – an anti-inflammatory
phenotype induced by intracellular cholesterol. The basis for this is
rooted in the LXRs and PPARs, which are important nuclear recep-
tors. The ligands for these receptors include lipids, and in addition
to regulating many steps of their metabolism, LXRs and PPARs
can also suppress inflammatory signaling in macrophages (42).
For example, a recent study demonstrated that cholesterol-loading
induced LXR-dependent downregulation of inflammatory gene
expression in macrophages as a consequence of the accumulation
of the cholesterol precursor desmosterol (43).
Indirect mechanisms that link cholesterol to macrophage inflam-
mation. It has been long known that T cells participate in plaque
inflammation (4). For example, using flow cytometry of whole
aortic digests, Galkina et al. could demonstrate the presence of
diverse cell-types of the adaptive immune system in the athero-
sclerotic plaque and the surrounding adventitia (44). Moreover,
the same group showed that antigen presentation to CD4+ T cells
in the arterial wall causes local T cell activation and the secretion
of pro-inflammatory cytokines, which promote atherosclerosis by
maintaining chronic inflammation and inducing foam cell forma-
tion (45). Other studies have shown a direct pro-inflammatory
role of intracellular cholesterol in T cells, mediated by cholesterol-
induced nano-clustering of T cell receptors (46). In addition, mice
lacking T cells can have a significant reduction in atherosclerosis
progression (47). Some studies, however, have demonstrated only
a minor role for T cells in atherosclerosis progression (48).
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FIGURE 1 | Summary of how changes in plasma cholesterol level and
in cellular cholesterol content affect macrophage polarization and
kinetics in atherosclerotic plaque progression and regression. Left
panel: An increase in non-HDL cholesterol (mainly VLDL cholesterol and
LDL cholesterol) in mouse models has been linked to an increase in
monocyte recruitment into atherosclerotic plaques, with their subsequent
polarization to M1 macrophages, which are retained. This ultimately leads
to atherosclerotic plaque progression, as evident by plaque enlargement.
The failure to clear dead macrophages by efferocytosis results in the
appearance of the necrotic core. Right panel: An opposite effect has been
demonstrated in atherosclerosis regression models, where a reduction in
non-HDL-C or a selective increase in HDL-C (representing an increase in
functional HDL particles) induces a decrease in plaque size and
macrophage content (from decreased monocyte recruitment and
macrophage retention), as well as enrichment in the expression of
markers of the M2 state. Improved efferocytosis is also expected under
these conditions, with shrinkage of the necrotic core. There is an increase
in collagen content, likely from decreased MMP production by the
macrophages. It is also likely that in a regression environment there are
decreases in the secretion of inflammatory cytokines and chemokines by
the macrophages as a result of the polarization of macrophages toward a
M2-like state. The different mechanisms by which cholesterol can drive
macrophage activation and polarization are divided into those direct – how
cholesterol affects macrophages, and indirect – how cholesterol affects
other cell types, for example by the secretion of pro-inflammatory
cytokines from T cells.
Another indirect effect on macrophage polarization/activation
by cholesterol is related to its being a major structural compo-
nent of progressing plaques, so its ongoing accumulation will
contribute to enlargement of the atheroma. This, in turn, is likely
to contribute to a hypoxic environment because as the atheroma
grows, the distance between the intimal cells from an oxygen sup-
ply will increase, particularly in mice, which have little capacity
to form vasa vasorum. Hypoxia triggers a heavy reliance on gly-
colysis for energy production and it has been recently recognized
that M1 cells are more glycolytic and M2 cells are more fatty acid
oxidizing, and that factors that promote one pathway of energy
generation over the other will promote the polarization state cor-
responding to the favored pathway (49). In addition, hypoxia can
contribute to the formation of the necrotic core, a characteristic
feature of advanced plaques that in humans increases the possi-
bility of rupture (50). In response to the hypoxic conditions in
the arterial wall, the development of vasa vasorum is enhanced,
and this has also been related to atherosclerosis progression, pos-
sibly by the recruitment of monocytes to the plaque through this
vascular route (51).
MACROPHAGE POLARIZATION AND LOCATION IN PROGRESSING
PLAQUES
Recent studies have found that although both M1 and M2
macrophage numbers are increased during human plaque pro-
gression, M1 macrophages were the predominant phenotype in
rupture-prone shoulder regions, whereas M2 markers were pre-
dominant in the adventitia and in stable cell-rich areas the of
plaque (19). In another study of human plaques, using the man-
nose receptor as a marker, M2 macrophages were found located
far from the lipid core of the plaque (52).
In mouse plaques, M1 macrophages tend to be diffusely distrib-
uted in, and characteristic of, progressing plaques at the usual age
that atherosclerotic mice are examined in detail (typically after
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12–16 of the consumption of a high-fat, high-cholesterol diet,
or ~16–20 weeks of age). Khallou-Laschet et al. have found in
apoE-deficient mice of a similar age, but with less advanced ath-
erosclerosis because they were maintained on a low-fat, chow diet
that these early plaques were infiltrated by M2 macrophages, with
M1 macrophages appearing later. Disease progression correlated
with the dominance of M1 over the M2 phenotype (53). Based
on serial histologic examination, they further propose that the
M2→M1 shift in balance was due to a phenotypic switch of the
infiltrated cells, but the data to support this were indirect and
did not exclude the possibility of replacement of macrophages by
new ones with a different phenotype, or the local proliferation
of M2-like tissue-resident cells, which has been reported in other
contexts as well (54, 55). In regard to the location of the differ-
ent macrophage phenotypes in the plaque, they show that M2
macrophages accumulated in the luminal side of the plaques in
young mice, while at 55 weeks of age, both M1 and M2 labeling
was evenly distributed across the plaque.
FUNCTIONAL CONSEQUENCES OF M1 POLARIZATION IN PROGRESSING
PLAQUES
The secretion of a wide range of cytokines and chemokines
(e.g., IL-1, TNFalpha, MCP-1) by M1 macrophages serves to
further activate macrophages, as well as other cell types in the
atheroma, such as endothelial and smooth muscle cells. There are
also effects on cellular lipid metabolism. In one study of human
plaques, macrophages with a marker of M2 macrophages had
small lipid droplets and in studies in vitro, this was associated
with a decreased ability to efflux cholesterol (52). In a study of
murine macrophages, when the cells were polarized to the M1
state, there was downregulation of ABCA1 and reduced choles-
terol efflux (56). If this were to happen in vivo, a vicious cycle
would be formed – cholesterol accumulation would contribute
to macrophage activation and M1 polarization, which would fur-
ther induces cholesterol accumulation. Before concluding that this
happens, given the divergent results on the effects of the M1 and
M2 phenotypes on cholesterol efflux, more research in this area is
clearly needed.
M1 macrophages also secrete chemokines (such as MCP-1) and
cytokines (such as IL-12) that induce chemotaxis of other white
blood cells (57, 58). In addition, M1 macrophages secrete several
matrix metallo-proteinases (MMPs), such as MMP2 and MMP9,
that can degrade the extracellular matrix in the plaque, which
is thought to lead to destabilization and rupture. Indeed, MMPs
were shown to co-localize with M1 macrophages in atherosclerotic
plaques (59).
ATHEROSCLEROSIS REGRESSION
Fatty streaks, the initial phase in the development of plaques,
were found in children as young as 3 years of age (60), with well-
established plaques developing by adolescence (61). Thus, while
most studies are focused on the progression of atherosclerosis and
finding means to delay it, the more frequent clinical scenario is that
by the time the patient comes for treatment of cardiovascular risk
factors, as a frequently middle-aged adult, he or she may already
have a significant burden of atherosclerosis, making the optimal
goal of therapy the induction of plaque regression.
Plaque regression can be defined in various ways, such as
a reduction in plaque size, plaque cholesterol content, plaque
macrophage number/percentage, or a decreased inflammatory
state. Of course, multiple changes can occur simultaneously, but
not in every case. For example, if the plaque macrophage content
decreases, while collagen content increases, as we have observed
experimentally in some models of regression [e.g., Ref. (16)], the
size may not change, but there will be less inflammation and more
stabilizing material. Nevertheless, though size changes may vary,
one consistent finding in various mouse models of atherosclero-
sis regression in which the issue of macrophage polarization was
examined, as will be summarized below, is that the plaque content
of M1 markers decreased, while those of M2 markers increased
[e.g., Ref. (16, 17, 62)].
ATHEROSCLEROSIS REGRESSION MODELS AND CHANGES IN PLAQUE
MACROPHAGES
Some of the currently available regression models include aortic
arch transplantation model (17, 63), Reversa mouse model (16,
64), adenoviral gene transfer of the LDL receptor, apoA1 or apoE,
a “hypomorphic apoE” model, administration of an inhibitor of
MTP,and infusion of apoA-I (the major protein in HDL) or apoA-I
mimetics (5, 65–69). By necessity, all models begin with a progres-
sion phase, in which the total plasma cholesterol, and in particular,
LDL-C and VLDL-C, are very high. After a certain period of time,
preferably at least 12–16 weeks of western diet (rich in saturated
fat and cholesterol) in order to accelerate in apoE-deficient-based
or enable in Ldl receptor-deficient-based models the development
of a complex atherosclerotic plaque, regression is typically induced
by a major change in the plasma lipid profile. This change is either
a reduction of LDL/VLDL-C or an increase in apoA1/HDL, both
of which would decrease the plaque content of cholesterol.
In the transplantation model, the plaque-containing aortic arch
from a donor apoE-deficient (apoE−/−) or Ldl receptor-deficient
(ldlr−/−) mouse fed a high-fat diet for 16 weeks is transferred into
the abdominal aorta of a normo-lipidemic wild-type recipient
mouse or an apoE−/− mouse made transgenic in human apoA1
(“hA1/EKO”) (17, 63, 70, 71). In either case, the regression of the
plaque in the transplanted arch occurs within a few days. The
advantage of the transplant model is that it can be used to test
the effects of specific genes on regression by using knock out or
transgenic strains, either for the donor or recipient mice, as well
as to conveniently study leukocyte trafficking in and out of the
plaques if the donors and recipients are mismatched in isoforms
of the pan-leukocyte marker for CD45. The disadvantage lies in
the technical difficulty in performing such a surgery in the mouse,
thereby limiting the throughput. In addition, there is inherent
inflammation induced by the surgery itself, which theoretically
can affect the process of regression, though control transplants
into apoE−/− mice are used as a standard control for these and
other effects related to the surgical procedures.
As noted above, HDL and its major protein, apoA1, can be
increased by injections of apoA1, apoA1 mimetics, or an adenovi-
ral vector expressing apoA1 (69, 72). In advanced atherosclerotic
plaques of apoE−/− mice, every other day injections of native
human apoA-I over only 1 week led to atherosclerosis regression,
as demonstrated by significant decreases in plaque lipid content,
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macrophage number, and an increase in collagen content; more-
over, apoA1 injections led to a significant reduction in the plaques
of inflammatory M1 and an increase in anti-inflammatory M2
macrophage markers, mannose receptor 1 and arginase 1 (73).
Treating mice with a recombinant adenovirus encoding human
apoA1 with relatively early atherosclerotic plaques resulted in a
70% reduction in aortic lesion area characterized by a significant
decrease in the fraction of lesions occupied by macrophages and
macrophage-derived foam cells. The inflammatory status of this
population of cells was not reported (69).
Another example for plaque regression induced by an increase
in HDL was shown with our collaborators using an inhibitor of
microRNA-33 (miR-33). miR-33 suppresses HDL formation in
the liver and its ability to efflux cholesterol from macrophages by
suppressing the expression of cholesterol transporter ATP-binding
cassette transporter 1 (ABCA1) (74). It was hypothesized that
inhibiting it by an antagomir (anti-miR-33) would promote ather-
osclerosis regression. Ldlr−/− mice with established plaques were
treated with anti-miR-33 over 4 weeks. As expected, anti-miR-33
treatment led to increased reverse cholesterol transport through
an increase in HDL levels and expression of ABCA1 in the liver
and macrophages. Consistent with that, and consistent with the
apoA1 injection study, atherosclerotic lesions regressed by anti-
miR-33 treatment, as shown by reduced plaque size, lipid and
macrophage content, increased collagen content and a diminished
inflammatory state of the macrophages in the plaque (75).
The Reversa (Ldlr−/−ApoB100/100Mttpfl/flMx1Cre+/+) mouse
is a non-surgical regression model, based on the Ldlr−/− mouse,
in which the hyperlipidemia can be reversed by inducing the con-
ditional knock out of the microsomal triglyceride transfer protein
(MTTP) gene (64). MTTP is required for the proper assembly of
VLDL, the precursor of LDL (76). The reversal of hyperlipidemia
by inactivation of MTTP leads to regression of atherosclerosis over
a few weeks accompanied by favorable changes in the composition
of the atherosclerotic plaque. Again,plaque lipid content decreases,
collagen content increases, and M1 markers are decreased while
M2 markers are increased in the plaque macrophages (16). The
advantage of the Reversa model is that it does not require any
surgery in order to get extreme reduction in LDL/VLDL-C. In
addition, it is important to note that unlike the transplant mod-
els, there is no increase in HDL after inducing the conditional
knock out of the MTTP gene. This might be part of the reason
for the reduced regression rate that can be seen in the Reversa
model compared with the transplant model. The disadvantage
of the model lies in the complicated genetic manipulations that
were performed to create it – there are four different gene inser-
tions/deletions in the Reversa mouse, and thus breeding it with
another transgenic/knock out mouse to test the importance of
a specific gene for regression is extremely time-intensive, mak-
ing bone marrow transfer for myeloid-specific factors a more
convenient manipulation.
The hepatic overexpression of apoE in apoE−/− or ldlr in
ldlr−/− mice is two gene transfer strategies to induce regression,
again by normalization of the lipid profile (5). The drawback of
this method is a potential immune response of the host after
the adenoviral gene transfer (77), which might complicate the
interpretation of the inflammatory state of cells in the plaque.
Also, especially with early versions of viral vectors, there can be
limitations related to the duration or amplitude of expression.
Inducing regression just by a diet change, from western diet to
chow, in the ldlr−/−mouse model has also been tried. Many times,
no significant changes have been observed,presumably because the
plasma cholesterol levels remain elevated, and perhaps, the exper-
iments were not continued long enough. In one recent report,
we and our collaborators have observed a reduction in plaque
macrophage content and inflammatory state over 4 weeks (78).
Notably, these favorable changes were impaired by hyperglycemia,
consistent with our previous report using Reversa mice (79).
Mechanisms for M2 macrophage enrichment in atherosclerosis
regression
There are two major questions we will consider in this section –
the origin of the M2 macrophages in regressing plaques and the
mechanisms for their increase.
One possibility is that the re-balancing from enrichment in M1
to M2 markers in regressing plaques represents either a change
in an individual cell, as can be accomplished in vitro by chang-
ing the cytokine environment, or as proposed to happen in the
“early to advanced” plaque transition in apoE−/− mice. Indeed, it
is generally accepted that the phenotype of a macrophage is quite
“plastic” and responsive to microenvironmental changes (9). It
is also possible that M1-like macrophages leave and are replaced
by M2-like cells, as occurs in wound healing. Support for this
scenario is our demonstration, particularly in the aortic transplan-
tation model,of emigration of macrophages from,and the ongoing
recruitment of monocytes to, plaques in the regression environ-
ment (80). A third possibility is the induction of the proliferation
of a resident population of yolk-sac-derived M2 macrophages,
as observed in other settings (54). Support for this possibility is
the recent demonstration in progressing plaques for macrophage
proliferation (55).
It is tempting to speculate that the pro-activating direct and
indirect effects of cholesterol described above are reversed under
conditions of regression, under which the plaque content of cellu-
lar and extracellular cholesterol is typically reduced. Little exper-
imental evidence, however, is available in vivo to prove this. Even
for factors with known cholesterol-removing function, such as
HDL, there could be lipid-independent reasons for their effects.
For example, we have recently reported that murine bone mar-
row derived-macrophages (BMDM) not loaded with cholesterol
will increase their M2 marker expression when incubated with
HDL (81) [though in human monocytes this was not found to
be the case (82)], and Latz and colleagues have found that HDL
will induce in macrophages the transcriptional regulator ATF3, a
repressor of a number of inflammatory factors (83). There is also
a study in which injection of apoA1 reduced skin inflammation
in ldlr−/−, apoA1−/− DKO mice (which show signs of autoimmu-
nity) by augmenting the effectiveness of the lymph node Treg cells
(84); Tregs were shown to induce an M2 polarization in yet another
study (15). In this example, there may have been a lipid-removal
aspect in that apoA1−/− mice are deficient in cholesterol efflux
because of reduced numbers of HDL particles. Although unre-
lated directly to macrophage polarization, it has been shown that
defects in cholesterol efflux can enrich the plasma membranes of
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monocyte precursors in the bone marrow with cholesterol, which
results in their greater proliferation, circulating monocytosis, and
increased entry into plaques of monocytes, which subsequently
promotes atherogenesis (85). Importantly, we have recently found
that this mechanism might also be related to the impairment of
atherosclerosis regression in diabetes (7).
Turning to the issue of what regulates the enrichment in M2
macrophages in regressing plaques, there are no results to discuss
at this time, but there are a number of possibilities. As mentioned
earlier, potent cytokines that polarize macrophages are IL-4 and
IL-13. These can be derived from a variety of leukocytes, namely
Th2 lymphocytes, eosinophils, and basophils. Even if one or more
of these types of leukocytes were the source of polarizing signals,
there is still the mystery of how the change in the lipoprotein/lipid
environment causes either the recruitment of the cells to the plaque
or the stimulation of secretion from either pre-existing or newly
recruited cells.
Functional contribution of M2 polarized cells to atherosclerosis
regression
Another major and incompletely understood area is the require-
ment for, and the function of, the enrichment in M2 macrophages
in atherosclerosis regression. Because their properties include tis-
sue remodeling and inflammation resolution, it is tempting to
attribute such changes in regressing plaques to M2 macrophages.
This would be consistent with studies in which treatment of
ldlr−/− mice with IL-13 resulted in pre-existing plaques the
following: an increase in collagen, a reduction in vascular cell
adhesion molecule-1 (VCAM-1)-dependent monocyte recruit-
ment, decreased macrophage content, and the induction of
M2 macrophages, despite ongoing hyperlipidemia (86). Another
reflection of the importance of the M2 macrophages for regres-
sion comes from our studies in diabetic Reversa mice, in which
hyperglycemia impaired their enrichment in plaques despite lipid
lowering and limited the favorable changes in macrophage content
and inflammatory state (79).
The promotion of the resolution of inflammation by M2
macrophages in regressing plaques is likely a consequence of
their secretion of IL-10. The plaque remodeling may represent
at least two other properties of M2 macrophages, namely their
secretion of collagen (87) and their enhanced capacity for effe-
rocytosis (88). Efferocytosis is the clearance of apoptotic cells by
macrophages. During atherosclerosis progression, the ability to
store cholesterol in plaque macrophages in the form of choles-
teryl ester lipid droplets wanes and free cholesterol accumulates,
causing ER stress and apoptosis (89). If efferocytosis of the dying
cells does not keep up with their formation, the cellular debris
that are not cleared would be expected to accumulate and become
a necrotic core. Indeed, in both mouse and human plaques, As
plaques advance, the efferocytotic activity of their macrophages
decreases (50). Thus, an enrichment in M2 macrophages with
enhanced efferocytosis would be expected to clear apoptotic cells
and thereby stop, and even reverse, necrotic core expansion.
CONCLUDING REMARKS
During both the progression and the regression of atherosclerosis,
macrophages have central roles. While macrophage phenotypes
are diverse and form a continuum (90), we chose a simple and
dichotomous approach in order to emphasize the differences
between macrophage properties in atherosclerosis progression and
regression. M1 macrophages predominate in progression and con-
tribute to the inflammatory state, whereas M2 macrophages are
enriched in many models of regression and appear to participate
in inflammation resolution and plaque remodeling. Interestingly,
M2 macrophages seem to have a beneficial role even when plasma
cholesterol levels remain high [e.g., Ref. (17, 86)], and the oppo-
site is also true – M1 macrophages, though activated by direct and
indirect effects of cholesterol, have also been linked to an increase
in atherosclerosis progression despite similar levels of plasma cho-
lesterol, for example, in diabetes (91). Thus, there are complex
interactions between macrophage phenotypes and plasma choles-
terol levels, a situation likely to also exist with other known (and
yet to be discovered) risk factors.
As noted throughout this review, there are many areas in which
our knowledge of macrophage biology in plaques is inadequate.
Yet, it is already clear that the inflammatory state of these cells is
dynamically influenced by multiple metabolic, genetic, and phar-
macologic factors. Deeper understanding of how these factors
effect changes in plaque macrophages will likely advance the devel-
opment of new strategies to reduce the huge burden of cardiovas-
cular morbidity and mortality that persists with existing therapies.
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